Irene Yeh

Identifying cancer-related mutations can be challenging, particularly when they occur at low levels or in complex regions of the genome. While short-read sequencing is commonly used for analyzing DNA, it has limitations when examining complex or repetitive regions of a genome. Long-read sequencing can help, but there is still a higher error rate compared to short-read sequencing. Researchers at The University of Hong Kong addressed this gap with ClairS, a tool designed to identify small cancer-related genetic mutations.

Early dementia with Lewy bodies and early Parkinson’s disease share several symptoms and are often misdiagnosed in early stages. It is critical to accurately distinguish the two diseases because of their contrasting disease paths. Reliable early diagnostic markers that can help track disease progression are key to preventing misdiagnosis and ensuring patients receive the correct treatment. Fortunately, walking behaviors may be early diagnostic markers for neurodegeneration.

During the 2025 Integrative Healthcare Symposium, GLP-1s were one of the main topics, especially regarding their impact on weight loss and obesity treatment. But for Monique Class, co-founder of The Center for Functional Medicine and The Institute for Functional Nursing, GLP-1s are more than just weight loss drugs. During her presentation, she proposed that GLP-1s can be used as metabolic, neurobehavioral, and anti-inflammatory tools that can catalyze sustainable changes when used strategically—specifically, through microdosing.

Patient recruitment remains a “never-ending challenge,” as described by Laszlo Vasko, senior director of R&D Therapeutic Enabling Innovation Technologies at Johnson & Johnson. Despite efforts to leverage real-world data to alleviate the difficulties, there has not been a surefire solution. During April’s Bio-IT World Conference & Expo, panelists gathered to discuss the roots of the problem and share ideas that could potentially solve this issue.